During Easter, Hubro Therapeutics attended the American Association for Cancer Research (AACR) with its poster.
The poster demonstrates how to early detect and monitor a relevant biomarker, and was linked to the company’s vision of developing FMPV-1 as a prophylactic cancer vaccine. During the session, a variety of industry and academic representatives visited the poster and discussed the technology and potential areas of application with Mr. Kvalheim Eriksen, Project Leader Exploratory Research who attended the poster session on behalf of the company. “Feedback and discussions were highly interesting, and the technology creates excitement in the scientific communities”, Mr. Kvalheim Eriksen reports.
